Problem
Conventional gut microbiome testing often relies on stool samples, which can be inconvenient and costly. MicrobioTx aims to make gut health profiling more accessible through a simpler testing approach.
Its Gut Function Test uses a finger-prick blood sample to analyse metabolites associated with gut microbes. The company also offers personalised probiotic formulations and nutrition recommendations based on individual gut profiles.
MicrobioTx launched its Gut Function Test commercially in 2024, following clinical validation and regulatory approval, as reported at launch. In April 2026, it introduced an IBS Risk Score combining microbiome profiling and metabolite analysis.
The company was co-founded by Akanksha Gupta, a healthcare professional with pharmaceutical industry experience, and Dr Palok Aich, a microbiome researcher. Their combined expertise spans healthcare commercialisation and scientific research.
MicrobioTx has received equity backing from Axilor Ventures and research grant support for product development. The funding supports its efforts to translate microbiome research into accessible preventive healthcare solutions.
|
Category |
Details |
|---|---|
|
Company |
MicrobioTx Health Pvt. Ltd. |
|
HQ |
Bengaluru, Karnataka |
|
Founded |
2022 |
|
Co-founders |
Akanksha Gupta and Dr Palok Aich |
|
Core offering |
Gut microbiome testing and personalised wellness |
|
Lead product |
Gut Function Test (GFT) |
|
New offering |
IBS Risk Score |
|
Technology |
AI-driven metabolite analysis |
|
Funding |
Equity backing from Axilor Ventures; research grants |
|
Next |
Expand into additional health conditions and international markets |
Disclaimer: This profile is based on publicly available information and company disclosures. Clinical and regulatory claims should be verified with the company before publication.